González-Gamboa Linda Mariana, Barocio-Ramírez Ana Karen, Rocha-Muñoz Alberto Daniel, de Santos-Ávila Fabiola, Meda-Lara Rosa M, González-López Laura, Gámez-Nava Jorge Iván, Gómez-Bañuelos Eduardo, Chavarria-Avila Efrain, Durán-Barragán Sergio, Navarro-Hernández Rosa Elena, Pizano-Martínez Oscar Enrique, Nuñez-Atahualpa Lourdes, Vázquez-Del Mercado Mónica
From the *Departamento de Psicología Básica, Centro Universitario de Ciencias de la Salud (CUCS), Universidad de Guadalajara, Guadalajara; †Centro Universitario de Tonalá (CUTonalá), Universidad de Guadalajara, Tonalá; and ‡Departamento de Medicina Interna-Reumatología, Hospital General Regional No. 110, Instituto Mexicano del Seguro Social; §Unidad de Investigación, Unidad Médica de Alta Especialidad, Hospital de Especialidades del Centro Médico Nacional de Occidente, Instituto Mexicano del Seguro Social; and ∥Instituto de Investigación en Reumatología y del Sistema Músculo Esquelético, ¶Departamento de Disciplinas Metodológicas, Filosóficas e Instrumentales, and #Departamento de Clínicas Médicas, Centro Universitario de Ciencias de la Salud, and **División de Medicina Interna, Servicio de Reumatología, OPD Hospital Civil "Dr. Juan I. Menchaca," Universidad de Guadalajara, Guadalajara, Jalisco, Mexico.
J Clin Rheumatol. 2016 Dec;22(8):399-404. doi: 10.1097/RHU.0000000000000463.
The aim of this study was to investigate the main factors associated to a diminished health-related quality of life (HRQoL) evaluated by INCAVISA (Health-Related Quality of Life Inventory for Latin American Patients) in patients with rheumatoid arthritis (RA).
Female, 18 years or older, RA (American College of Rheumatology 1987 criteria and American College of Rheumatology/European League against Rheumatism 2010 criteria) patients who attended the outpatient rheumatology department of the Hospital Civil "Dr. Juan I. Menchaca," Guadalajara, Mexico, matched with healthy controls were included. Patients with any known comorbidities or treatment with antidepressive drugs were excluded. Trained physicians performed the RA clinical evaluation and INCAVISA. All data were analyzed using SPSS 21.0 software (SPSS Inc, Chicago, IL); P < 0.05 was considered statistically significant.
Patients with polypharmacy (≥3 drugs) had a lower HRQoL by INCAVISA. The number of drugs, total comorbidities, and DAS-28 (Disease Activity Score on 28 Joints) were negatively correlated with total INCAVISA. In multivariate analysis, DAS-28 and polypharmacy were independent predictors for a negative perception of HRQoL evaluated by INCAVISA in RA patients.
Disease activity and disability secondary to RA have a negative impact in the HRQoL. Other factors such as the number of drugs prescribed to these patients have been shown to be important for the negative perception of their HRQoL evaluated by INCAVISA.
